Enterprise Value
7.713B
Cash
718.3M
Avg Qtr Burn
N/A
Short % of Float
6.74%
Insider Ownership
2.58%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
DEFINITY® Room Temperature Details Suboptimal echocardiograms | Approved Quarterly sales | |
RELISTOR Details Constipation | Approved Quarterly sales | |
PYLARIFY Details Prostate cancer, Cancer | Approved Quarterly sales | |
AZEDRA® (iobenguane I 131) Details Pheochromocytoma , Paraganglioma , Solid tumor/s | Approved Quarterly sales | |
Flurpiridaz F 18 Details Heart disease, Coronary artery disease | NDA Acceptance for review | |
¹⁷⁷Lu-PNT2002 Details Cancer, Castration-resistant prostate cancer | Phase 3 Data readout | |
NAV-4694 (18-flutafuranol) Details Alzheimer's disease | Phase 3 Update | |
1095 (PSMA-targeted iodine-131 labeled small molecule) Details Prostate cancer, Glioblastoma, Cancer | Phase 2 Data readout | |
¹⁷⁷Lu-DOTA-RM2 Details Cancer, Prostate cancer | Phase 1/2 Initiation | |
LNTH-1404 Details Prostate cancer, Cancer | Failed Discontinued |